-
Publication Venue For
-
The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from CHAMP-HF..
24:762-770.
2022
-
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction..
24:782-790.
2022
-
Prioritizing prevention of de novo and worsening chronic heart failure..
24:653-656.
2022
-
Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology..
24:603-619.
2022
-
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
2022
-
Heart failure quality of care and in-hospital outcomes during the COVID-19 pandemic: findings from the Get With The Guidelines-Heart Failure registry.
2022
-
Classifying heart failure based on ejection fraction: imperfect but enduring.
2022
-
Changes in inferior vena cava area represent a more sensitive metric than changes in filling pressures during experimental manipulation of intravascular volume and tone..
24:455-462.
2022
-
Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction..
24:431-441.
2022
-
Worsening renal function in acute heart failure in the context of diuretic response..
24:365-374.
2022
-
In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable..
24:227-229.
2022
-
Corrigendum to 'Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials' [Eur J Heart Fail 2016;18:684-692]..
23:1991.
2021
-
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry..
23:1844-1854.
2021
-
Another reason to embrace quadruple medical therapy for heart failure: medications enabling tolerance of each other..
23:1525-1528.
2021
-
Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map..
23:1468-1476.
2021
-
Effect of patient-centered transitional care services on patient-reported outcomes in heart failure: sex-specific analysis of the PACT-HF randomized controlled trial..
23:1488-1498.
2021
-
Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of 'too little, too late'..
23:1514-1517.
2021
-
Can we prevent infections in patients with left ventricular assist devices?.
23:1416-1418.
2021
-
Clinical inertia and medical therapy for heart failure: the unintended harms of 'first, do no harm'..
23:1343-1345.
2021
-
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial..
23:1300-1312.
2021
-
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial..
23:1226-1237.
2021
-
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial..
23:1217-1225.
2021
-
Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial..
23:1147-1155.
2021
-
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations..
23:1076-1084.
2021
-
Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first-in-human clinical trial..
23:1134-1143.
2021
-
The lower is not always the better: a more comprehensive understanding of loop diuretics in heart failure..
23:1120-1121.
2021
-
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics..
23:1040-1048.
2021
-
Sodium-glucose co-transporter 2 inhibitors for heart failure: clinical trial efficacy and clinical practice effectiveness..
23:1023-1025.
2021
-
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association..
23:352-380.
2021
-
A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure..
23:175-185.
2021
-
Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study..
23:58-67.
2021
-
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium..
22:2175-2186.
2020
-
Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial..
22:2026-2034.
2020
-
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society..
22:1945-1960.
2020
-
Depression and heart failure: the lonely comorbidity..
22:2007-2017.
2020
-
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials..
22:2160-2171.
2020
-
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology..
22:1966-1983.
2020
-
Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan..
22:2018-2025.
2020
-
Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Reply..
22:1935.
2020
-
Hospitalizations for heart failure during the COVID-19 pandemic: making sense of the known knowns, known unknowns, and unknown unknowns..
22:1752-1754.
2020
-
The real world of de novo heart failure: the next frontier for heart failure clinical trials?.
22:1786-1789.
2020
-
All rise! Orthostatic hypotension in heart failure. Letter regarding the article 'Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients'..
22:1741.
2020
-
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial..
22:1649-1658.
2020
-
Regional adiposity and heart failure with preserved ejection fraction..
22:1540-1550.
2020
-
Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial..
22:1684-1693.
2020
-
Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial..
22:1451-1461.
2020
-
Patient-reported outcomes for heart failure with preserved ejection fraction: conducting quality studies on quality of life..
22:1019-1021.
2020
-
Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity..
22:1009-1018.
2020
-
The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial - insights from ASCEND-HF..
22:1022-1031.
2020
-
Trends in prevalence of comorbidities in heart failure clinical trials..
22:1032-1042.
2020
-
One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System..
22:859-867.
2020
-
Association between body surface area and prescribed doses of guideline-directed medications among international patients with heart failure and reduced ejection fraction..
22:754-758.
2020
-
Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission..
22:683-691.
2020
-
Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAX-AHF-2 trial..
22:726-738.
2020
-
Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard..
22:422-424.
2020
-
Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis..
22:472-485.
2020
-
Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis..
22:315-329.
2020
-
Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry..
22:103-112.
2020
-
Post-discharge haemodilution, congestion, and clinical outcomes among patients hospitalized for heart failure with reduced ejection fraction: results from the EVEREST trial..
22:164-167.
2020
-
Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial..
21:1596-1604.
2019
-
Heart failure treatment and the art of medical decision making..
21:1510-1514.
2019
-
Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial..
21:1561-1570.
2019
-
Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial..
21:1472-1476.
2019
-
Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial..
21:1426-1433.
2019
-
Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?.
21:1398-1401.
2019
-
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial..
21:1270-1278.
2019
-
Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial..
21:1279-1287.
2019
-
In-hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time..
21:1008-1011.
2019
-
Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction..
21:974-984.
2019
-
Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure..
21:1022-1031.
2019
-
Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score..
21:770-778.
2019
-
Erratum to 'The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions' [Eur J Heart Fail 2018;20:963-972]..
21:819.
2019
-
Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy..
21:373-381.
2019
-
Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges..
21:286-296.
2019
-
Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care..
21:121-124.
2019
-
Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION..
21:63-70.
2019
-
Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials..
20:1735-1743.
2018
-
Relationship between timing of trial randomization, protocol completion, and clinical outcomes among patients hospitalized for heart failure: from the ASTRONAUT trial..
20:1760-1763.
2018
-
Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction..
20:1601-1610.
2018
-
Nomenclature in heart failure: a call for objective, reproducible, and biologically-driven terminology..
20:1379-1381.
2018
-
Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry..
20:1281-1289.
2018
-
Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study..
20:1257-1266.
2018
-
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum..
20:1230-1239.
2018
-
Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy..
20:1227-1229.
2018
-
Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply..
20:1166.
2018
-
Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years..
20:1068-1071.
2018
-
Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes..
20:1031-1038.
2018
-
The role of angiotensin receptor-neprilysin inhibitors in cardiovascular disease-existing evidence, knowledge gaps, and future directions..
20:963-972.
2018
-
Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home?.
20:723-724.
2018
-
Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial..
20:677-686.
2018
-
Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure..
20:504-510.
2018
-
Percutaneous edge-to-edge leaflet repair: a solution to the risk-treatment paradox of mitral regurgitation complicated by pulmonary hypertension?.
20:595-597.
2018
-
Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?.
20:471-473.
2018
-
Sudden cardiac death following admission for acute heart failure: adding insult to injury..
20:533-535.
2018
-
Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF..
20:304-314.
2018
-
Considering the duration of heart failure: using the past to predict the future..
20:382-384.
2018
-
Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial..
20:281-291.
2018
-
Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality..
20:295-303.
2018
-
Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe?.
20:317-322.
2018
-
Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study..
19:1520-1529.
2017
-
The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors..
19:1390-1400.
2017
-
A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure..
19:1310-1320.
2017
-
Protein turnover in the failing heart: an ever-changing landscape..
19:1218-1221.
2017
-
Improving heart failure health: is there a secret Swedish sauce?.
19:1117-1118.
2017
-
A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial..
19:1001-1010.
2017
-
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?.
19:974-986.
2017
-
Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction..
19:870-872.
2017
-
Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS)..
19:739-747.
2017
-
Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure..
19:728-738.
2017
-
Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study..
19:800-809.
2017
-
Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes..
19:595-602.
2017
-
Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure..
19:673-681.
2017
-
Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial..
19:552-562.
2017
-
Carotid body resection for sympathetic modulation in systolic heart failure: results from first-in-man study..
19:391-400.
2017
-
Diabetes and heart failure in the crosshairs: where is the target?.
19:66-68.
2017
-
Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme..
18:1508-1517.
2016
-
Biomarker-based risk prediction in the community..
18:1342-1350.
2016
-
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis..
18:1238-1243.
2016
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment..
18:1162-1171.
2016
-
Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization..
18:1190-1192.
2016
-
Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality..
18:1041-1050.
2016
-
A Gordian knot: disentangling comorbidities in heart failure..
18:759-761.
2016
-
Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study..
18:830-839.
2016
-
Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials..
18:684-692.
2016
-
Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome..
18:641-649.
2016
-
Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF..
18:424-432.
2016
-
Signature of circulating microRNAs in patients with acute heart failure..
18:414-423.
2016
-
Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy..
18:290-297.
2016
-
Optimizing clinical use of biomarkers in high-risk acute heart failure patients..
18:269-280.
2016
-
The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF..
18:306-313.
2016
-
Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design..
18:160-168.
2016
-
Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study..
17:1262-1270.
2015
-
Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials..
17:1252-1261.
2015
-
Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study..
17:1133-1143.
2015
-
In-hospital worsening heart failure..
17:1104-1113.
2015
-
Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction?.
17:991-993.
2015
-
Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial..
17:1022-1031.
2015
-
Reclassifying heart failure: time for disruptive innovation?.
17:879-880.
2015
-
Same protocol, different continents, different patients: should we continue to conduct global heart failure trials?.
17:875-878.
2015
-
Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial..
17:725-734.
2015
-
Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial..
17:697-706.
2015
-
Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial..
17:591-600.
2015
-
REPORT-HF: the unique blend of global heart failure registry and longitudinal cohort study..
17:472-474.
2015
-
Impact of surgical ventricular reconstruction on sphericity index in patients with ischaemic cardiomyopathy: follow-up from the STICH trial..
17:453-463.
2015
-
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)..
17:301-312.
2015
-
Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction..
17:135-143.
2015
-
Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme..
17:196-204.
2015
-
Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial..
17:109-118.
2015
-
Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial..
17:98-108.
2015
-
Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study..
16:1362-1371.
2014
-
Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF..
16:1230-1240.
2014
-
Persistent angina pectoris in ischaemic cardiomyopathy: increased rehospitalization and major adverse cardiac events..
16:854-860.
2014
-
International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial..
16:614-624.
2014
-
Decongestion in acute heart failure..
16:471-482.
2014
-
Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study..
16:403-408.
2014
-
The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial..
16:334-341.
2014
-
Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved..
16:33-40.
2014
-
Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties..
16:76-85.
2014
-
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial..
15:1401-1411.
2013
-
Sex-specific acute heart failure phenotypes and outcomes from PROTECT..
15:1374-1381.
2013
-
Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document..
15:1082-1094.
2013
-
Risk assessment for incident heart failure in individuals with atrial fibrillation..
15:843-849.
2013
-
Heart failure in elderly patients: distinctive features and unresolved issues..
15:717-723.
2013
-
Targeting anti-beta-1-adrenergic receptor antibodies for dilated cardiomyopathy..
15:724-729.
2013
-
Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction..
15:679-689.
2013
-
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial..
15:551-559.
2013
-
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF..
15:456-464.
2013
-
Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy..
15:258-266.
2013
-
Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF)..
15:334-341.
2013
-
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation..
15:324-333.
2013
-
Paced QRS duration as a predictor for clinical heart failure events during right ventricular apical pacing in patients with idiopathic complete atrioventricular block: results from an observational cohort study (PREDICT-HF)..
15:352-359.
2013
-
Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial..
15:194-202.
2013
-
Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial..
15:61-68.
2013
-
Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study..
14:1257-1264.
2012
-
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes..
14:1056-1066.
2012
-
Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation..
14:939-945.
2012
-
Impairment of activities of daily living and incident heart failure in community-dwelling older adults..
14:581-587.
2012
-
The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction..
14:605-612.
2012
-
Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE-HF..
14:395-403.
2012
-
Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure..
14:45-53.
2012
-
Dangerous diuretics or death defying drugs?.
13:1157-1158.
2011
-
Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry..
13:945-952.
2011
-
Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF..
13:961-967.
2011
-
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction..
13:148-153.
2011
-
Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function..
12:1238-1246.
2010
-
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction..
12:1229-1237.
2010
-
Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study..
12:1130-1139.
2010
-
The STICH trial: evidence-based conclusions..
12:1028-1030.
2010
-
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme..
12:738-745.
2010
-
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme..
12:557-565.
2010
-
Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study..
12:499-507.
2010
-
Red blood cell distribution width and 1-year mortality in acute heart failure..
12:129-136.
2010
-
Adherence to medication according to sex and age in the CHARM programme..
11:1092-1098.
2009
-
Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial..
11:795-801.
2009
-
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).
2021
-
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry.
2020
-
Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF.
2018
-
Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.
2017
-
Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF.
2015